Hypertension , diabetes mellitus and dyslipidemia as per latest guidelines
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
2025 2026 hypertension diabetes dyslipidemia latest guidelines summary
Finding Sources
Finding Sources
Finding Sources
Searching the Web
2025 hypertension management guidelines JNC ACC AHA blood pressure targets
Reading File
Reading File
Reading File
Searching the Web
2025 ADA diabetes mellitus guidelines treatment targets HbA1c
Searching the Web
2025 ACC AHA dyslipidemia guidelines LDL targets statin therapy
Reading Web Page
guidelines diagnosis treatment targets drug therapy classification
Finding Sources
Finding Sources
I now have comprehensive data from the latest 2025/2026 guidelines. Let me compile the full structured response.
Hypertension, Diabetes Mellitus & Dyslipidemia: Latest Guidelines (2025-2026)
PART 1: HYPERTENSION
2025 AHA/ACC/Multisociety High Blood Pressure Guideline
This is the first major update since 2017, published by the ACC/AHA and 12 co-endorsing societies.
Classification
| Category | Systolic (mmHg) | Diastolic (mmHg) |
|---|---|---|
| Normal | < 120 | and < 80 |
| Elevated | 120 - 129 | and < 80 |
| Stage 1 Hypertension | 130 - 139 | or 80 - 89 |
| Stage 2 Hypertension | ≥ 140 | or ≥ 90 |
| Hypertensive Crisis | > 180 | and/or > 120 |
Treatment Targets
- Universal target: < 130/80 mmHg for all adults
- Additional goal: SBP < 120 mmHg is encouraged where tolerable (reduces CV events further)
- SBP < 130 mmHg is now a Class 1A recommendation to reduce cognitive impairment and dementia risk
- Frail/elderly/institutionalized patients: individualize target (avoid adverse effects)
- Severe hypertension (> 180/120 mmHg) without acute target organ damage: treat outpatient with oral agents - no need for routine emergency room visits
Risk Assessment
- The 2025 guideline replaces the Pooled Cohort Equation with the PREVENT Equation (Predicting Risk of Cardiovascular Disease EVENTs) for 10-year CVD risk estimation
When to Start Pharmacotherapy
| BP Range | 10-yr CVD Risk (PREVENT) | Recommended Action |
|---|---|---|
| ≥ 140/90 mmHg (Stage 2) | Any risk | Start drug therapy immediately + lifestyle |
| 130-139/80-89 mmHg (Stage 1) | ≥ 7.5% | Start drug therapy + lifestyle |
| 130-139/80-89 mmHg (Stage 1) | < 7.5% | Lifestyle modification x 3-6 months; if BP still not at goal, start pharmacotherapy |
| Elevated (120-129) | Any | Lifestyle modification only |
First-Line Pharmacotherapy
The guideline continues to recommend four first-line drug classes:
- Thiazide-type diuretics - chlorthalidone preferred over hydrochlorothiazide
- Long-acting dihydropyridine calcium channel blockers (CCBs) - e.g., amlodipine
- ACE inhibitors (ACEi) - e.g., ramipril, lisinopril
- Angiotensin receptor blockers (ARBs) - e.g., losartan, valsartan
ACEi and ARBs should NOT be combined with each other.
- Prefer once-daily dosing and single-pill combinations (SPCs) to improve adherence
- Multidisciplinary team-based care is emphasized (pharmacists, nutritionists, APPs)
Lifestyle Modifications (All stages, foundational)
- DASH diet (low sodium < 2,300 mg/day)
- Weight reduction (each 1 kg loss ~ 1 mmHg SBP reduction)
- Regular aerobic exercise (150 min/week moderate intensity)
- Limit alcohol
- Smoking cessation
Special Situations
- Resistant hypertension: ≥ 3 drugs at max dose, still uncontrolled - consider renal denervation (new recommendations with shared decision-making)
- Cognitive decline/dementia prevention: SBP < 130 mmHg - Class 1A
- Pregnancy: individualized targets; standard first-lines contraindicated
PART 2: DIABETES MELLITUS
ADA Standards of Care in Diabetes 2025 (+ 2026 update released Dec 2025)
Diagnostic Criteria
| Test | Diabetes | Prediabetes |
|---|---|---|
| Fasting glucose | ≥ 126 mg/dL | 100-125 mg/dL |
| 2-hr OGTT | ≥ 200 mg/dL | 140-199 mg/dL |
| HbA1c | ≥ 6.5% (48 mmol/mol) | 5.7-6.4% |
| Random glucose + symptoms | ≥ 200 mg/dL | - |
Glycemic Targets (Non-pregnant adults)
| Target | HbA1c |
|---|---|
| Most non-pregnant adults (standard) | < 7.0% (< 53 mmol/mol) |
| Stringent (newly diagnosed, long life expectancy, no CVD, no hypoglycemia risk) | < 6.5% (< 48 mmol/mol) |
| Less stringent (limited life expectancy, advanced complications, high hypoglycemia risk, extensive comorbidities) | < 8.0% (< 64 mmol/mol) |
Glucose targets:
- Preprandial: 80-130 mg/dL (4.4-7.2 mmol/L)
- Postprandial (peak): < 180 mg/dL (< 10.0 mmol/L)
2025 update - Deintensification: Explicit language added to reduce/stop medications when risks exceed benefits (especially insulin, sulfonylureas, meglitinides).
Pharmacologic Management - Type 2 Diabetes
First-Line
- Metformin remains first-line at diagnosis (unless contraindicated - eGFR < 30, contrast studies, etc.)
Individualized Add-on Therapy (evidence-based selection)
| Drug class | Preferred when |
|---|---|
| GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) | Established CVD or high CV risk; obesity/weight management priority; CKD |
| SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) | Heart failure (especially HFrEF); CKD with proteinuria; CV risk reduction; weight loss |
| DPP-4 inhibitors (sitagliptin, saxagliptin) | Hypoglycemia risk; renal impairment; weight neutral |
| Sulfonylureas | Cost-effective option when hypoglycemia risk is managed |
| Insulin (basal, then intensification) | HbA1c ≥ 10% or BG ≥ 300 mg/dL with symptoms; type 1 DM (mandatory) |
| Pioglitazone (TZD) | NAFLD/MASLD; insulin resistance; low cost |
| Tirzepatide (GIP/GLP-1 dual agonist) | Superior HbA1c and weight reduction; CVD benefit emerging |
2025 key point: If HbA1c is ≥ 1.5% above goal, start with dual combination therapy from the outset rather than step-up monotherapy.
Monitoring
| Parameter | Frequency |
|---|---|
| HbA1c | Every 3 months if not at goal; every 6 months if stable |
| Blood pressure | Every visit |
| Lipids | Annually |
| eGFR + UACR | Annually |
| Eye exam | Annually (Type 1: after 5 yrs; Type 2: at diagnosis) |
| Foot exam | Annually |
CGM (Continuous Glucose Monitoring): Now recommended alongside HbA1c. Key metrics:
- Time in Range (TIR): 70-180 mg/dL (target > 70%)
- Time Below Range (TBR): < 70 mg/dL (target < 4%)
- Time Above Range (TAR): > 180 mg/dL (target < 25%)
Cardiovascular & Renal Protection
- In patients with established ASCVD or high CV risk: GLP-1 RA or SGLT2i is preferred regardless of HbA1c level
- In patients with heart failure: SGLT2i is Class 1A
- In patients with CKD (eGFR 20-60, UACR ≥ 200): SGLT2i + finerenone (MRA) combination now recommended
- Blood pressure target in diabetics: < 130/80 mmHg
Type 1 Diabetes
- Insulin therapy is mandatory (multiple daily injections or insulin pump)
- Automated Insulin Delivery (AID/closed-loop systems) strongly endorsed
- Adjunct: low-dose SGLT2i (empagliflozin, dapagliflozin) may be added in T1DM with high CV/renal risk (with appropriate monitoring for DKA risk)
Hypoglycemia Classification
| Level | Glucose | Management |
|---|---|---|
| Level 1 | < 70 mg/dL (3.9 mmol/L) | 15-20g fast-acting carbohydrates; recheck in 15 min |
| Level 2 | < 54 mg/dL (3.0 mmol/L) | Immediate treatment; glucagon if unable to self-treat |
| Level 3 | Altered consciousness or physical status | Glucagon (all high-risk patients should have it prescribed) |
PART 3: DYSLIPIDEMIA
2026 ACC/AHA Multisociety Guideline for Management of Blood Cholesterol
(Released March 13, 2026 - replaces 2018 guideline)
This is the most recent update and carries several major shifts.
Risk Stratification (10-year ASCVD risk using PREVENT-ASCVD tool)
| Category | 10-year Risk | LDL-C Target |
|---|---|---|
| Low | < 3% | Lifestyle only |
| Borderline | 3% to < 5% | LDL-C < 100 mg/dL |
| Intermediate | 5% to < 10% | LDL-C < 100 mg/dL |
| High | ≥ 10% | LDL-C < 70 mg/dL |
| Very High Risk (secondary prevention with ASCVD) | N/A | LDL-C < 55 mg/dL |
Major change: Specific LDL-C targets are reinstated (abandoned in 2013, partially in 2018, now fully restored and aligned with ESC guidelines).
Coronary Artery Calcium (CAC) Score - Now Treatment-Defining
| CAC Score | Recommendation |
|---|---|
| CAC = 0 | May defer statin therapy (if no other risk enhancers) |
| CAC 100-999 AU | Statin therapy; target LDL-C < 70 mg/dL and non-HDL < 100 mg/dL (Class 1) |
| CAC ≥ 1,000 AU | At least 50% LDL-C reduction AND target < 55 mg/dL (Class 1) |
Drug Therapy Hierarchy
Step 1 - First-line:
- Statins remain the foundation of lipid-lowering therapy
- High-intensity: atorvastatin 40-80 mg, rosuvastatin 20-40 mg (≥ 50% LDL-C reduction)
- Moderate-intensity: atorvastatin 10-20 mg, rosuvastatin 10 mg, simvastatin 20-40 mg (30-49% reduction)
Step 2 - Add-on non-statin therapy (if LDL-C target not met):
| Agent | Mechanism | Indication |
|---|---|---|
| Ezetimibe | Inhibits NPC1L1 cholesterol absorption | First non-statin add-on; oral, well-tolerated |
| Bempedoic acid | Inhibits ATP-citrate lyase (upstream of statins) | Statin-intolerant patients; oral |
| PCSK9 monoclonal antibodies (evolocumab, alirocumab) | Prevent LDL-R degradation → markedly reduce LDL | Very high risk; LDL still not at target on statin + ezetimibe |
| Inclisiran (siRNA) | Reduces hepatic PCSK9 synthesis | Alternative to PCSK9 mAbs; twice-yearly injection; cardiovascular outcome data awaited |
Triglycerides
| Level | Classification | Management |
|---|---|---|
| < 150 mg/dL | Normal | Lifestyle |
| 150-499 mg/dL | Mild-moderate hypertriglyceridemia | Lifestyle; icosapentaenoic acid (EPA/omega-3) if ≥ 135 mg/dL with ASCVD |
| ≥ 500 mg/dL | Severe | Fibrates (fenofibrate, gemfibrozil) to prevent pancreatitis |
- Icosapentaenoic acid (Vascepa/EPA): CV outcome benefit shown (REDUCE-IT trial) in patients with TG 135-499 mg/dL on statin with established CVD or diabetes
Lifestyle Foundation (All patients)
- Avoid tobacco
- Heart-healthy diet (reduce saturated fat, trans fat; increase fiber)
- Regular aerobic exercise + strength training
- Maintain healthy weight
- Healthy sleep habits (new emphasis in 2026 guideline)
- PREVENT-ASCVD risk calculator (age 30-79, no known ASCVD, LDL 70-189 mg/dL) - provides both 10-year AND 30-year risk
Special Populations (2026 additions)
- Familial Hypercholesterolemia (FH): Earlier, more intensive treatment; cascade screening of family members
- Diabetes: Treated as high risk - LDL-C < 70 mg/dL; PCSK9i if not at goal
- CKD Stage 3-4: Intensive LLT; avoid high-dose statins with severe CKD
- Pregnancy: Statins contraindicated; bile acid sequestrants may be used
- Cancer patients: Risk-benefit assessment; LLT often continued through treatment
- HIV: Increased ASCVD risk; statin therapy recommended with attention to drug interactions
Quick Reference Summary
| Condition | Key Target | First-Line Drug | Major 2025/2026 Change |
|---|---|---|---|
| Hypertension | BP < 130/80 mmHg | Thiazide / CCB / ACEi / ARB | PREVENT replaces Pooled Cohort Eq; Stage 1 low-risk: lifestyle first 3-6 months |
| Type 2 DM | HbA1c < 7.0% | Metformin ± GLP-1 RA or SGLT2i | Stronger deintensification language; tirzepatide; CGM metrics alongside HbA1c |
| Dyslipidemia | LDL-C < 55 mg/dL (very high risk) | Statin | LDL-C targets reinstated; CAC score now treatment-defining; bempedoic acid as add-on |
Sources:
This is a shared conversation. Sign in to Orris to start your own chat.